Preblick Ryan 4

What Happened
Ryan Preblick, Chief Financial Officer of Indivior Pharmaceuticals (INDV), was granted a total of 150,868 restricted stock units (RSUs) in two awards reported Feb 9–10, 2026. One award for 37,358 RSUs was granted Feb 10, 2026 (nominal $0 price). A second, derivative award for 113,510 RSUs was certified as earned on Feb 9, 2026 (nominal $0 price) following satisfaction of prior performance conditions. No cash was paid for these awards — they are compensation grants, not open-market purchases.

Key Details

• Transaction dates: 2026-02-09 (113,510 RSUs, derivative/performance-certified) and 2026-02-10 (37,358 RSUs). Report filed 2026-02-12 (timely).
• Price: $0.00 per RSU (awarded, not purchased). Total awarded: 150,868 RSUs.
• Vesting: 37,358 RSUs vest in three equal annual installments beginning Feb 10, 2027 (subject to continued service). The 113,510 RSU award was a conditional 2023 performance award; performance was certified Feb 9, 2026 and it vests (subject to continued employment) on Mar 3, 2026, after which vested shares are subject to a two‑year holding period before release.
• Shares owned after transaction: not specified in the filing.
• Transaction code: A = Award/Grant. The 113,510 entry is reported as a derivative award (performance-based).
• Filing timeliness: Reported within required Form 4 timeframe (not marked late).
• Exhibit: Power of Attorney filed as Exhibit 24.

Context: These entries are equity compensation grants, common for executives as part of pay and retention programs. They do not involve an open-market purchase or sale and are contingent on continued employment (and, for the larger award, prior performance certification and a subsequent holding period). Such grants signal company compensation events but are not direct buys or sells that reveal immediate trading intent.